Press Releases

USAgainstAlzheimer’s Disappointed with Medicare’s Final Decision To Limit Coverage of Innovative Diagnostic Tool

Despite public protest, decision will bar thousands of Alzheimer’s and dementia patients from access to PET beta-amyloid scans that help optimize diagnoses



AfricanAmericanNetworkAgainstAlzheimer’s Launches with New Report on Alzheimer’s Disparities

African American Network Against Alzheimer’s to Partner with Award Winning Playwright Garrett Davis

Davis, Founder of the Forget Me Not Project, Brings Innovative Approach to Advocacy in Effort to Fulfill Network’s Mission to End Alzheimer’s by 2020

Earlier this month, CMS proposed a policy that would severely limit Medicare beneficiaries being evaluated for dementia from an innovative new technology capable of providing a more precise diagnosis as to the form of dementia and enabling patients to receive timely and effective treatments and care. USAgainstAlzheimer’s has been highly critical of this proposal and has marshaled our resources to change this policy. Comments from USAgainstAlzheimer’s as well as our affiliate network ResearchersAgainstAlzheimer’s were submitted on Friday to CMS.

Hundreds of Alzheimer’s Advocates Urge CMS to Support Coverage of Innovative Diagnostic Scans

Safe and effective PET beta-amyloid scans will allow doctors to advise patients on the proper course of care and speed clinical trials

WASHINGTON, DC – Nearly 350 Alzheimer’s advocates submitted comments to the Centers for Medicare & Medicaid Services (CMS) this week, urging the agency to provide coverage for a tool able to more precisely diagnose patients being evaluated for dementia.


^ Back to Top